BIO-RAD LABORATORIES, INC. Equity Securities, FV-NI, Unrealized Gain
BIO-RAD LABORATORIES, INC. (BIO) reported Equity Securities, FV-NI, Unrealized Gain of $872.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2026-02-13
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2025-06-30 was $326.60M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2025-03-31 was $29.00M, a 92.79% decline year-over-year.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-09-30 was $761.10M, a 1690.82% increase year-over-year.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2024-03-31 was $402.30M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for fiscal 2025 was $872.60M.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for fiscal 2020 was $4.50B, a 121.35% increase from fiscal 2019.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for fiscal 2019 was $2.03B, a 234.23% increase from fiscal 2018.
- BIO-RAD LABORATORIES, INC. equity securities, fv-ni, unrealized gain for fiscal 2018 was $607.70M.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 9 month | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2025-12-31 | $872.60M 10-K · filed 2026-02-13 | |||
| 2025-06-30 | $326.60M 10-Q · filed 2025-07-31 | $355.70M 10-Q · filed 2025-07-31 | ||
| 2025-03-31 | $29.00M 10-Q · filed 2025-05-01 | |||
| 2024-09-30 | $761.10M 10-Q · filed 2024-10-31 | |||
| 2024-03-31 | $402.30M 10-Q · filed 2024-05-08 | |||
| 2023-09-30 | $42.50M 10-Q · filed 2023-10-27 | $1.62B derived: sum of 2 quarters · filed 2023-10-27 | ||
| 2023-06-30 | $1.58B 10-Q · filed 2023-08-04 | $1.60B 10-Q · filed 2023-08-04 | ||
| 2022-06-30 | $1.28B 10-Q · filed 2022-07-29 | $5.73B derived: sum of 2 quarters · filed 2022-07-29 | ||
| 2022-03-31 | $4.45B 10-Q · filed 2022-04-29 | |||
| 2021-09-30 | $4.87B 10-Q · filed 2021-10-29 | $5.90B derived: sum of 2 quarters · filed 2021-10-29 | $7.08B 10-Q · filed 2021-10-29 | $7.98B derived: sum of 4 quarters · filed 2021-10-29 |
| 2021-06-30 | $1.03B 10-Q · filed 2021-07-30 | $2.21B 10-Q · filed 2021-07-30 | $3.11B derived: sum of 3 quarters · filed 2021-07-30 | $4.69B derived: sum of 4 quarters · filed 2021-07-30 |
| 2021-03-31 | $1.18B 10-Q · filed 2021-04-30 | $2.08B derived: sum of 2 quarters · filed 2021-04-30 | $3.66B derived: sum of 3 quarters · filed 2021-04-30 | $4.85B derived: sum of 4 quarters · filed 2021-04-30 |
| 2020-12-31 | $904.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $2.48B derived: sum of 2 quarters · filed 2021-02-16 | $3.67B derived: sum of 3 quarters · filed 2021-02-16 | $4.50B 10-K · filed 2021-02-16 |
| 2020-09-30 | $1.58B 10-Q · filed 2020-10-30 | $2.76B derived: sum of 2 quarters · filed 2020-10-30 | $3.59B 10-Q · filed 2020-10-30 | $4.24B derived: sum of 4 quarters · filed 2020-10-30 |
| 2020-06-30 | $1.18B 10-Q · filed 2020-07-31 | $2.01B 10-Q · filed 2020-07-31 | $2.66B derived: sum of 3 quarters · filed 2020-07-31 | $2.27B derived: sum of 4 quarters · filed 2020-07-31 |
| 2020-03-31 | $827.70M 10-Q · filed 2020-05-08 | $1.47B derived: sum of 2 quarters · filed 2020-05-08 | $1.08B derived: sum of 3 quarters · filed 2020-05-08 | $1.80B derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-12-31 | $646.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $255.40M derived: sum of 2 quarters · filed 2020-03-02 | $971.90M derived: sum of 3 quarters · filed 2020-03-02 | $2.03B 10-K · filed 2020-03-02 |
| 2019-09-30 | -$390.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $325.80M derived: sum of 2 quarters · filed 2019-11-01 | $1.39B 10-Q · filed 2019-11-01 | $572.40M derived: sum of 4 quarters · filed 2019-11-01 |
| 2019-06-30 | $716.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.78B 10-Q · filed 2019-08-06 | $963.10M derived: sum of 3 quarters · filed 2019-08-06 | $1.28B derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | $1.06B 10-Q · filed 2019-05-10 | $246.60M derived: sum of 2 quarters · filed 2019-05-10 | $564.60M derived: sum of 3 quarters · filed 2019-05-10 | |
| 2018-12-31 | -$812.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$494.60M derived: sum of 2 quarters · filed 2019-04-01 | $607.70M 10-K · filed 2019-04-01 | |
| 2018-09-30 | $318.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $1.42B 10-Q · filed 2018-11-05 | ||
| 2018-06-30 | $1.10B 10-Q · filed 2018-08-09 |